UroGen Pharma Ltd.
URGN
$19.48
-$0.30-1.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 94.24M | 91.87M | 90.40M | 89.36M | 85.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 94.24M | 91.87M | 90.40M | 89.36M | 85.01M |
| Cost of Revenue | 10.80M | 9.48M | 8.88M | 8.70M | 8.61M |
| Gross Profit | 83.43M | 82.39M | 81.52M | 80.67M | 76.40M |
| SG&A Expenses | 140.87M | 127.72M | 120.05M | 110.85M | 103.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 216.70M | 198.73M | 186.08M | 173.10M | 164.70M |
| Operating Income | -122.47M | -106.86M | -95.68M | -83.73M | -79.69M |
| Income Before Tax | -150.82M | -135.26M | -124.04M | -111.34M | -109.65M |
| Income Tax Expenses | 4.15M | 3.17M | 2.83M | 4.04M | 3.94M |
| Earnings from Continuing Operations | -154.97 | -138.43 | -126.87 | -115.38 | -113.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -154.97M | -138.43M | -126.87M | -115.38M | -113.58M |
| EBIT | -122.47M | -106.86M | -95.68M | -83.73M | -79.69M |
| EBITDA | -122.18M | -106.58M | -95.35M | -83.28M | -79.12M |
| EPS Basic | -3.32 | -3.10 | -3.04 | -2.96 | -3.09 |
| Normalized Basic EPS | -2.00 | -1.88 | -1.85 | -1.78 | -1.87 |
| EPS Diluted | -3.32 | -3.10 | -3.04 | -2.96 | -3.09 |
| Normalized Diluted EPS | -2.00 | -1.88 | -1.85 | -1.78 | -1.87 |
| Average Basic Shares Outstanding | 185.29M | 178.05M | 167.69M | 156.81M | 146.01M |
| Average Diluted Shares Outstanding | 185.29M | 178.05M | 167.69M | 156.81M | 146.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |